Aldeyra Therapeutics (NASDAQ:ALDX) Issues Earnings Results

Posted by Francis Steltz on Aug 8th, 2026

Aldeyra Therapeutics (NASDAQ:ALDX – Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09), FiscalAI reports.

Aldeyra Therapeutics Trading Down 2.5%

NASDAQ:ALDX opened at $1.55 on Friday. Aldeyra Therapeutics has a 12-month low of $1.07 and a 12-month high of $6.17. The firm has a market cap of $93.50 million, a price-to-earnings ratio of -3.37 and a beta of 1.21. The company’s 50-day moving average is $1.83 and its two-hundred day moving average is $2.73.

Wall Street Analysts Forecast Growth

ALDX has been the topic of a number of research reports. Wall Street Zen upgraded Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Weiss Ratings downgraded Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 20th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Aldeyra Therapeutics currently has an average rating of “Hold” and an average target price of $5.50.

Read Our Latest Research Report on Aldeyra Therapeutics

Insider Buying and Selling at Aldeyra Therapeutics

In other news, CEO Todd C. Brady acquired 250,000 shares of Aldeyra Therapeutics stock in a transaction that occurred on Wednesday, June 3rd. The shares were acquired at an average price of $1.67 per share, with a total value of $417,500.00. Following the completion of the purchase, the chief executive officer owned 1,721,298 shares of the company’s stock, valued at approximately $2,874,567.66. This represents a 16.99% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Aldeyra Therapeutics by 2.6% during the third quarter. Vanguard Group Inc. now owns 3,591,869 shares of the biotechnology company’s stock worth $18,750,000 after purchasing an additional 90,276 shares during the last quarter. AQR Capital Management LLC lifted its position in Aldeyra Therapeutics by 275.4% during the second quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock worth $5,645,000 after buying an additional 1,081,257 shares during the period. Geode Capital Management LLC lifted its position in Aldeyra Therapeutics by 0.8% during the second quarter. Geode Capital Management LLC now owns 1,146,597 shares of the biotechnology company’s stock worth $4,392,000 after buying an additional 8,769 shares during the period. Kennedy Capital Management LLC boosted its stake in Aldeyra Therapeutics by 61.9% in the 3rd quarter. Kennedy Capital Management LLC now owns 1,112,213 shares of the biotechnology company’s stock worth $5,806,000 after buying an additional 425,245 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Aldeyra Therapeutics by 2.2% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 968,751 shares of the biotechnology company’s stock valued at $5,018,000 after buying an additional 21,200 shares during the period. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

(Get Free Report)

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.